- Trials with a EudraCT protocol (222)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (1)
222 result(s) found for: Molecule.
Displaying page 1 of 12.
| EudraCT Number: 2008-000091-24 | Sponsor Protocol Number: TAK-442 202 | Start Date*: 2008-12-02 | |||||||||||
| Sponsor Name:Takeda Global Research & Development Centre (Europe) Ltd. | |||||||||||||
| Full Title: A Phase 2, Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of TAK-442 in Subjects With Acute Coronary Syndromes | |||||||||||||
| Medical condition: acute coronary syndromes | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) BE (Completed) DE (Completed) EE (Completed) HU (Completed) BG (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2006-000873-32 | Sponsor Protocol Number: RGHT000255 | Start Date*: 2006-08-02 |
| Sponsor Name:Royal Group of Hospitals Trust | ||
| Full Title: Effect of statin therapy on monocyte function in the metabolic syndrome. | ||
| Medical condition: Metabolic syndrome, the essential feature of which is central obesity | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: GB (Prematurely Ended) | ||
| Trial results: View results | ||
| EudraCT Number: 2013-005178-23 | Sponsor Protocol Number: BR-TUM-ICG-IV | Start Date*: 2014-01-30 |
| Sponsor Name:Jules Bordet Institute | ||
| Full Title: Study of the (intravenously injected) Indocyanine Green distribution in the margins of breast cancer after tumorectomy | ||
| Medical condition: Imaging of tumours and their margins after intravenous injection of Indocyanine Green to breast cancer patients | ||
| Disease: | ||
| Population Age: Adults | Gender: Female | |
| Trial protocol: BE (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2016-000879-24 | Sponsor Protocol Number: IJB-BC-NEORHEA-2016 | Start Date*: 2017-03-23 | |||||||||||
| Sponsor Name:Institut Jules Bordet | |||||||||||||
| Full Title: Neoadjuvant Biomarker ResearcH Study of Palbociclib Combined with Endocrine Therapy in Estrogen Receptor Positive/ HER2 Negative Breast CAncer | |||||||||||||
| Medical condition: Primary breast cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: BE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2009-014796-51 | Sponsor Protocol Number: 120BC201 | Start Date*: 2010-02-02 | |||||||||||
| Sponsor Name:Biogen Idec Ltd. | |||||||||||||
| Full Title: Phase 2a, open-label, randomized, noncomparative study of BIIB021 in combination with exemestane in women with hormone receptor-positive, advanced metatatic breast cancer who have progressed on a n... | |||||||||||||
| Medical condition: Advanced Metastatic Breast Cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2006-001368-22 | Sponsor Protocol Number: DG-041-CV-008 | Start Date*: 2006-06-01 |
| Sponsor Name:deCODE genetics ehf. | ||
| Full Title: A randomized, double blind, placebo controlled phase II evaluation of the pharmacokinetics, pharmacodynamics and safety of DG-041 in PAD patients | ||
| Medical condition: Peripheral arterial disease | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: IS (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2013-004496-12 | Sponsor Protocol Number: BR-ICG-IV-NACT | Start Date*: 2013-12-05 |
| Sponsor Name:Institut Jules Bordet | ||
| Full Title: Study of the (intravenously injected) ICG distribution in tumour bearing breasts and in axillary pieces of dissection of patients who have received neo-adjuvant therapy for histologically proven ma... | ||
| Medical condition: imaging of tumours and their margins after intravenous injection of Indocyanine Green to breast cancer patients | ||
| Disease: | ||
| Population Age: Adults | Gender: Female | |
| Trial protocol: BE (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2020-004167-29 | Sponsor Protocol Number: NA | Start Date*: 2021-03-15 |
| Sponsor Name:CHU de Liège | ||
| Full Title: Study of the noninferiority of an oral versus intravenous administration of tranexamic acid in total hip arthroplasty | ||
| Medical condition: Bleeding in total hip arthroplasty | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: BE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2005-003349-15 | Sponsor Protocol Number: ARPH-CL-03 | Start Date*: 2006-02-07 | |||||||||||
| Sponsor Name:Ariston Pharmaceuticals, Inc | |||||||||||||
| Full Title: Intranasal Hydroxocobalamin (AST-726) Treatment for Prohylaxis of Migraine: a Placebo-Controlled, Clinical Study | |||||||||||||
| Medical condition: Migraine headache with and without aura | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FI (Completed) GB (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2013-004978-95 | Sponsor Protocol Number: VildaMMC | Start Date*: 2014-03-12 |
| Sponsor Name:KULeuven | ||
| Full Title: the influence of a DPP-4 inhibitor, vildaglitpin, on hunger and the migrating motor complex in healthy volunteers | ||
| Medical condition: healthy volunteers no medical condition, drug will be studied because they are known to influence gastric motility | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: BE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2008-002673-13 | Sponsor Protocol Number: APA-IIb | Start Date*: Information not available in EudraCT |
| Sponsor Name:PSKS | ||
| Full Title: Anti-inflammatory pulmonal therapy of CF-patients with Amitriptyline and Placebo | ||
| Medical condition: Deficiency of the Cftr-molecule results in accumulation of ceramide in respiratory epithelial cells. Ceramide triggers a pro-inflammatory and -apoptotic status in cystic fibrosis patients. Amitript... | ||
| Disease: | ||
| Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |
| Trial protocol: DE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2010-020171-23 | Sponsor Protocol Number: 4SC-201-3-2010 | Start Date*: 2010-10-04 | |||||||||||
| Sponsor Name:4SC AG | |||||||||||||
| Full Title: A phase I/II study to evaluate safety, tolerability, pharmacokinetics and efficacy of resminostat (4SC-201) in combination with a second-line treatment in patients with k-ras mutated advanced color... | |||||||||||||
| Medical condition: Advanced or metastasized colorectal carcinoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2016-000301-37 | Sponsor Protocol Number: EFC13738 | Start Date*: 2018-10-09 | ||||||||||||||||
| Sponsor Name:Genzyme Corporation | ||||||||||||||||||
| Full Title: Open label, Two Cohort (with and without Imiglucerase), Multicenter Study to Evaluate Pharmacokinetics, Safety, and Efficacy of Eliglustat in Pediatric Patients with Gaucher Disease Type 1 and Type 3 | ||||||||||||||||||
| Medical condition: Congenital, hereditary and neonatal diseases | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
| Trial protocol: SE (Completed) IT (Trial now transitioned) NL (Ongoing) ES (Ongoing) Outside EU/EEA GB (GB - no longer in EU/EEA) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2017-004859-22 | Sponsor Protocol Number: UF9888 | Start Date*: 2018-04-12 | |||||||||||
| Sponsor Name:University Hospital of Monptellier | |||||||||||||
| Full Title: Treatment of hepatocellular carcinoma on child cirrhosis A/B7 by intra-arterial injection of a Lipiodol and Idarubicin emulsion : a multicentric single-arm phase II study | |||||||||||||
| Medical condition: The research hypothesis is that hepatic locoregional treatment without embolization, using a more cytotoxic anticancer molecule (Idarubicin) than those conventionally used, would be more effective. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2022-002947-23 | Sponsor Protocol Number: DP10027 | Start Date*: 2023-04-14 | |||||||||||
| Sponsor Name:Acacia Pharma Ltd | |||||||||||||
| Full Title: Randomized, double-blind, Phase 2/3 study of IV amisulpride as prevention of post-operative nausea and vomiting in pediatric patients | |||||||||||||
| Medical condition: post-operative nausea and vomiting in pediatric patients | |||||||||||||
|
|||||||||||||
| Population Age: Newborns, Infants and toddlers, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2015-005685-30 | Sponsor Protocol Number: 2015-005685-30 | Start Date*: 2016-04-08 |
| Sponsor Name:Hôpital Erasme | ||
| Full Title: Evaluation of microcirculation alterations in cardiac surgery, by FMD (Flow Mediated vasoDilation), Near Infrared Spectrophotometry (NIRS) and biological analysis | ||
| Medical condition: Cardiac pathology eligible for surgery | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: BE (Prematurely Ended) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2019-004999-19 | Sponsor Protocol Number: 191001 | Start Date*: 2020-06-16 | |||||||||||
| Sponsor Name:Department of infectious diseases, Hvidovre Hospital | |||||||||||||
| Full Title: Changes in weight, body composition and metabolic parameters after switch to dolutegravir/lamuvidine compared to continued treatment with dolutegravir/abacavir/lamuvidine for virologically suppress... | |||||||||||||
| Medical condition: Human immunodeficiency viruses (HIV) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DK (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2007-004772-39 | Sponsor Protocol Number: LYSINE1 | Start Date*: 2007-12-19 |
| Sponsor Name:Sahlgrenska Acadademy, GU | ||
| Full Title: AN EXPLORATORY OPEN LABEL STUDY OF ADJUNCTIVE L-LYSINE TREATMENT IN PATIENTS WITH SCHIZOPHRENIA | ||
| Medical condition: Schizophrenia and related psychoses | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: SE (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2008-006491-30 | Sponsor Protocol Number: CHB 08 03 | Start Date*: 2009-02-06 |
| Sponsor Name:Centre Henri Becquerel | ||
| Full Title: Etude prospective, multicentrique, de phase II testant la faisabilité d’un traitement d’entretien par l’alemtuzumab chez des patients porteurs de leucémie lymphoïde chronique, traités et répondant ... | ||
| Medical condition: Chronic lymphoid leukemia in complete remission (CR) or partial remission (PR) | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: FR (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2021-003601-21 | Sponsor Protocol Number: ZX-2021-FES-ESTROTIMP-4. | Start Date*: 2021-09-22 | |||||||||||
| Sponsor Name:Zionexa | |||||||||||||
| Full Title: Impact of 18F-FES TEP on therapeutical management in patients with metastatic breast cancer, ER positive and HER2 negative, in relapse after a first line of treatment combining hormonal therapy | |||||||||||||
| Medical condition: Patients with metastatic breast cancer initially presenting with overexpression of estrogen receptors (ERs) and absence of overexpression of HER2, relapsing after a first therapeutic line combining... | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: FR (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.